Coherus BioSciences Forges Key Oncology Alliance with Janssen

Coherus BioSciences US19249H1032

Coherus BioSciences has secured a significant partnership for its clinical development efforts, aligning with Janssen Research & Development, a Johnson & Johnson company. The collaboration will evaluate a promising oncology candidate for metastatic castration-resistant prostate cancer (mCRPC), marking a strategic step for the biopharmaceutical firm. This move arrives as the company’s shares show considerable strength in the early part of the trading year.

The alliance centers on a Phase 1b combination study. Coherus’s investigational anti-CCR8 antibody, Tagmokitug (CHS-114), will be tested alongside Janssen’s therapeutic agent, Pasritamig. A critical feature of the agreement is its structure: Coherus will act as the study sponsor, while Janssen will supply Pasritamig.